Clinuvel Pharmaceuticals Limited logo

Clinuvel Pharmaceuticals Limited

HQ Melbourne, Australia · Egham · Baar · Dublin · San Mateo

Mission

Translate scientific advances into products for medical conditions without adequate alternatives

Health & BiotechIndependently selected by SlideDoor

Products and services

  • SCENESSE (afamelanotide 16mg)

Clinuvel develops melanocortin-based therapies. Its commercial lead product SCENESSE is an afamelanotide implant used to prevent phototoxicity in adults with erythropoietic protoporphyria (EPP). PRÉNUMBRA and other development programs should be distinguished from approved commercial treatments.

What stands out for senior leaders

Clinuvel connects pharmaceutical development with the commercial delivery of a treatment for a specific unmet medical need. Its lead product SCENESSE is an afamelanotide implant for adults with erythropoietic protoporphyria, giving the company a concrete therapeutic offering rather than a research-only proposition.

The company’s stated purpose centres on translating scientific advances into products for conditions without alternatives. Its leadership materials describe Philippe Wolgen’s role in reformulation, regulatory approval and distribution. For a senior leader, the relevant distinction is between an established commercial therapy and the separate development programs that may or may not become future treatments.

Leadership areas

  • Clinical development
  • Regulatory affairs
  • Pharmaceutical research

The honest trade-off

Commercial approval for SCENESSE does not establish approval, effectiveness or commercial readiness for PRÉNUMBRA or other research programs.

Questions leaders ask about Clinuvel Pharmaceuticals Limited

Where is Clinuvel headquartered?
The official contact page identifies Melbourne, Australia, as the head office.
Is PRÉNUMBRA the same as an approved SCENESSE offering?
No. The product page describes PRÉNUMBRA as a separate injectable afamelanotide formulation under development, including clinical-trial use.

Sources

Last checked November 2026

Headquarters
Melbourne, Australia
CEO
Dr Philippe Wolgen
Offices
Melbourne, Egham, Baar, Dublin, San Mateo, Singapore

Checked against a public source

Website

More companies in Melbourne